The contribution of pathogenic variants in breast cancer susceptibility genes to familial breast cancer risk

Familial breast cancer: Pinning down susceptibility genes beyond BRCA Women with the heritable form of breast cancer often harbor mutations in cancer-linked genes other than the usual suspects, BRCA1 and BRCA2. Slavin, Maxwell, Lilyquist, Joseph, and colleagues from major national and international...

Descripción completa

Guardado en:
Detalles Bibliográficos
Autores principales: Thomas P. Slavin, Kara N. Maxwell, Jenna Lilyquist, Joseph Vijai, Susan L. Neuhausen, Steven N. Hart, Vignesh Ravichandran, Tinu Thomas, Ann Maria, Danylo Villano, Kasmintan A. Schrader, Raymond Moore, Chunling Hu, Bradley Wubbenhorst, Brandon M. Wenz, Kurt D’Andrea, Mark E. Robson, Paolo Peterlongo, Bernardo Bonanni, James M. Ford, Judy E. Garber, Susan M. Domchek, Csilla Szabo, Kenneth Offit, Katherine L. Nathanson, Jeffrey N. Weitzel, Fergus J. Couch
Formato: article
Lenguaje:EN
Publicado: Nature Portfolio 2017
Materias:
Acceso en línea:https://doaj.org/article/22db8878f67d44d09b2b4f5b6bb65e1c
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
Descripción
Sumario:Familial breast cancer: Pinning down susceptibility genes beyond BRCA Women with the heritable form of breast cancer often harbor mutations in cancer-linked genes other than the usual suspects, BRCA1 and BRCA2. Slavin, Maxwell, Lilyquist, Joseph, and colleagues from major national and international cancer centers studied 2134 women with familial breast cancer who tested negative for BRCA1/2 gene mutations. The researchers sequenced 26 known or proposed breast cancer susceptibility genes and found mutations in approximately 1 in every 12 of the study subjects. They then further broke down the susceptibility genes into those that confer high-, moderate- or low-risk—although not all the proposed breast cancer genes reached statistical significance and, as such, their clinical importance remains unclear. The results support adding some of the high- and moderate-risk genes to multi-panel diagnostic tests that aim to determine the likelihood of a women developing heritable breast cancer.